Allergy

Allergy Amulet Secures $3.3 Million To Launch World's Smallest and Fastest Consumer Food Allergen Sensor

Wednesday, August 12, 2020 - 2:30pm

The company has developed the world's smallest and fastest consumer food allergen sensor, which is capable of testing foods for common allergenic ingredients in seconds.

Key Points: 
  • The company has developed the world's smallest and fastest consumer food allergen sensor, which is capable of testing foods for common allergenic ingredients in seconds.
  • Individuals with food allergies: It makes testing for food allergens easy, giving people additional assurances that their food is safe.
  • Allergy Amulet empowers the food allergy community to feel secure in their everyday lives by alleviating fears about what's in their food.
  • As the world's smallest and fastest consumer food allergen sensor, Allergy Amulet is designed to fit into every lifestyle, whether on a keychain, a necklace, a wristband, or in a pocket.

ARCADIA clinical studies to investigate potential new treatment for people with moderate-to-severe atopic dermatitis

Tuesday, August 11, 2020 - 11:00am

It is characterised by an allergic response driven by a subset of immune cells called Type 2 helper T cells.

Key Points: 
  • It is characterised by an allergic response driven by a subset of immune cells called Type 2 helper T cells.
  • Dr. Jonathan Silverberg, MD, PhD, MPH.said: "It is crucial that we continue to research new treatment options for moderate-to-severe atopic dermatitis.
  • ARCADIA 1 & 2 are identical Phase 3 randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of nemolizumab (CD14152) in subjects with moderate-to-severe atopic dermatitis.
  • The studies will also be evaluating the efficacy and safety of maintenance treatment with nemolizumab for up to an additional 32 weeks.

Global Ragweed Pollen Allergy Treatment Market to be valued at US$ 1,147.3 Million by 2027, Says Coherent Market Insights (CMI)

Monday, August 10, 2020 - 3:15pm

The global ragweed pollen allergy treatment market is expected to witness significant growth owing to research & development activities and drug approvals by regulatory authority.

Key Points: 
  • The global ragweed pollen allergy treatment market is expected to witness significant growth owing to research & development activities and drug approvals by regulatory authority.
  • The global ragweed pollen allergy treatment market is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027) owing to the rising focus of key industry players on developing novel ragweed pollen allergy treatments.
  • North America is expected to be the most lucrative region in the global ragweed pollen allergy treatment market owing to approvals of novel medication for pollen allergy treatment.
  • For instance, in April 2014, the U.S. FDA approved the novel ragweed allergy pill, Ragwitek, for treatment of ragweed pollen allergy.

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

Monday, August 10, 2020 - 12:30pm

Fast Track designation confirms the unmet medical need for patients who are at risk for allergic reactions including anaphylaxis but reluctant and hesitant to use the standard of care, subcutaneous and intramuscular injections.

Key Points: 
  • Fast Track designation confirms the unmet medical need for patients who are at risk for allergic reactions including anaphylaxis but reluctant and hesitant to use the standard of care, subcutaneous and intramuscular injections.
  • AQST-108 is a first of its kind oral sublingual film formulation delivering systemic epinephrine for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestives proprietary PharmFilm technologies.
  • Anaphylaxis is a potentially life-threatening systemic allergic reaction, with an estimated incidence of 50 to 112 episodes per 100,000 people per year.
  • PharmFilm and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

COVID-19 Impacts: Allergy Diagnostics Market will Accelerate at a CAGR of almost 13% through 2020-2024 | Expansion of Product Ranges Through M&A to Boost Growth | Technavio

Friday, August 7, 2020 - 4:30pm

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43789

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43789
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our allergy diagnostics market report covers the following areas:
    This study identifies increasing funding for allergy diagnostic devices as one of the prime reasons driving the allergy diagnostics market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the allergy diagnostics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Friday, August 7, 2020 - 1:00pm

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.

Key Points: 
  • Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.
  • A live webcast of the presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com .
  • Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies.
  • With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies.

Asthma and Allergy Foundation of America (AAFA) Appoints Melanie Carver Chief Mission Officer

Thursday, August 6, 2020 - 1:53pm

Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the organization.

Key Points: 
  • Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the organization.
  • As Chief Mission Officer, Carver will continue to lead AAFAs programmatic work as a community-focused organization.Included in that community focus, she will oversee AAFAs community outreach, marketing and communications, education, and asthma & allergy friendly Certification Program relations.
  • Melanie is the North Star of everything AAFA does and she is a part of the asthma and allergy community herself.
  • Carver is also playing a leading role in the organizations response to the COVID-19 pandemic, addressing asthma and allergy concerns.

IgGenix Completes $10 Million Series A Financing

Tuesday, August 4, 2020 - 12:30pm

IgGenix, Inc, today announced it completed a $10 million Series A financing.

Key Points: 
  • IgGenix, Inc, today announced it completed a $10 million Series A financing.
  • The prevalence of severe food allergy for both children and adults continues to increase worldwide, with recent studies indicating that more than 200 million people are impacted, said Mr. Hironaka, CEO of IgGenix.
  • Dr. Boismenu brings over 20 years of research, drug development, strategy and executive leadership expertise to IgGenix.
  • IgGenix seeks to change the face of allergic disease, empowering people to live life without the constant fear of a life-threatening allergic reaction.

NeoSan Labs Broad Spectrum Air Detox Treatment Purifies and Sterilizes the Air We Share

Sunday, August 2, 2020 - 4:00pm

In fact, indoor air contains 200 to 1,000% more toxins than outdoor air.

Key Points: 
  • In fact, indoor air contains 200 to 1,000% more toxins than outdoor air.
  • That's why NeoSan Labs introduced its easy-to-use, broad-spectrum Air Detox treatment that purifies and sterilizes the air we share.
  • NeoSan Labs 02 Air Detox is the only chemical product that eliminates irritants and hazardous agents that can cause asthma, allergic reactions, and chemical sensitivity, and neutralizes odors on a molecular level," says Greg Charillon, CEO of NeoSan Labs.
  • For more information about NeoSan Labs products, contact 877-400-9080, email gcharillon@neosanlabs.com or visit http://www.neosanlabs.com .

SmithFoods Inc. Issues Allergy Alert On Undeclared Cashew Allergen In Earth Grown Vegan Non-Dairy Almond Based Frozen Desserts

Saturday, August 1, 2020 - 2:54am

ORRVILLE, Ohio, July 31, 2020 /PRNewswire/ --SmithFoods Inc. announced that it is voluntarily recalling 16-oz pint packages of Earth Grown Vegan Non-Dairy Almond Based Frozen Desserts because it may contain an undeclared cashew allergen.

Key Points: 
  • ORRVILLE, Ohio, July 31, 2020 /PRNewswire/ --SmithFoods Inc. announced that it is voluntarily recalling 16-oz pint packages of Earth Grown Vegan Non-Dairy Almond Based Frozen Desserts because it may contain an undeclared cashew allergen.
  • People who have an allergy or severe sensitivity to cashews run the risk of a serious or life-threatening allergic reaction if they consume these products.
  • The product was also available for purchase by ALDI customers through the company's partnership with Instacart, a grocery delivery service.
  • Recalled UPC and lot codes are: